Upcoming Webinars

 

The Global Socioeconomic Impact of Rare Diseases: A Call for Action
Wednesday, May 22, 2024
10:00AM EDT | 2:00PM UTC | 4:00PM CEST

Are Clinical Outcome Assessments Sufficiently Valued?
Wednesday, May 29, 2024
10:00AM EDT | 2:00PM UTC | 4:00PM CEST

Assessing the Fiscal Burden of Obesity Using a Public Economic Framework
Thursday, May 30, 2024
10:00AM EDT | 2:00PM UTC | 4:00PM CEST

Overcoming the Barriers of Open-Source Modelling
Tuesday, June 11, 2024
12:00PM EDT | 4:00PM UTC | 6:00PM CEST

ISPOR Top 10 HEOR Trends - What Are the Key Themes for 2024-25?
Wednesday, June 12, 2024
10:00AM EDT | 2:00PM UTC | 4:00PM CEST

Most Recent


The Global Socioeconomic Impact of Rare Diseases: A Call for Action

May 2024

The webinar will begin with a (5-minute) introduction of the participants of the study to the ISPOR Rare Disease (RD) SIG, followed by an overview of the study objectives, its methodology and findings (25-minute). This will be followed by a (30-minute) Q&A moderated discussion. The novel study explored the burden of different RDs across a range of countries, including low-and-middle-income countries (LMICs). The diseases and countries were chosen to allow for a diverse and relevant representation of RD burden globally, aiming to capture cross-disease and cross-country unmet needs, and consequent areas for policy intervention.

Revolutionizing Systematic Reviews: Harnessing the Power of AI

May 2024

This webinar will provide a comprehensive overview of the current landscape of AI adoption in systematic reviews and showcase several state-of-the-art platforms revolutionizing the systematic review process.

Revolutionizing Clinical Trials: Harnessing Real-World Evidence to Drive Diversity and Clinical Implementation

Apr 2024

In this session, we'll discuss leveraging RWE to enhance diversity within clinical trials and expedite the translation of research findings into real-world clinical practice. Our expert panel will illuminate how RWE can address existing disparities in clinical trial participation, amplify the voices of underrepresented communities, and ultimately lead to more effective and equitable healthcare interventions.

Measuring the Indirect Costs Driving Financial Toxicity in Oncology

Apr 2024

In this webinar, experts will characterize financial toxicity from the patient perspective, suggest potential frameworks for incorporation of financial toxicity into economic evaluation, and discuss areas where further research is necessary.

Beyond the Boundaries of RCT Data: Connecting Trials to the Real-World

Apr 2024

Join Inovalon’s experts as they discuss the power of combining RCT with real-world data, through innovative data-linking techniques, to transform understanding of the patient journey to uncover invaluable insights into clinical and economic outcomes in the real-world.

Measuring Value in Oncology: Are We Keeping Pace with Science?

Mar 2024

This panel will discuss different perspectives on the utilization of these principles to advance value frameworks that help timely access to transformative treatments for people with cancer.

Clinical Outcomes



Beyond the Boundaries of RCT Data: Connecting Trials to the Real-World

Apr 2024

Join Inovalon’s experts as they discuss the power of combining RCT with real-world data, through innovative data-linking techniques, to transform understanding of the patient journey to uncover invaluable insights into clinical and economic outcomes in the real-world.

Preventing, Detecting, and Analyzing Data From Suspected Fraudulent Respondents in Online Surveys, with Examples From Health Preference Studies

Feb 2023

The workshop will use real-time polling to understand the audience’s experiences with data collection fraud online and the methods used to prevent and identify data collection fraud. We will encourage audience members to share their own strategies, learnings, and challenges.

Achieving Fit for Purpose Data from Wearables for Age-Related Diseases

Jan 2023

An ageing population means an urgent need for better and effective treatment for age-related illnesses. Despite billion-dollar investments for drug development for these conditions, especially neurogenerative diseases, there is a low success rate and it is a slow process.

Souring On SUCRAs: When Treatment Ranking Goes Wrong

Oct 2022

This webinar will explore what the SUCRA is, demonstrate how it can be meaningfully impacted by network composition (even in simple networks), and suggest corrections to common errors in the reporting of SUCRAs.


Economic Evaluation



Measuring the Indirect Costs Driving Financial Toxicity in Oncology

Apr 2024

In this webinar, experts will characterize financial toxicity from the patient perspective, suggest potential frameworks for incorporation of financial toxicity into economic evaluation, and discuss areas where further research is necessary.

Driving Health Outcomes: Exploring Value-Based Procurement

Aug 2023

Value-Based Procurement (VBP) is a critical element of a value-based healthcare system, offering a transformative purchase approach that addresses underlying barriers to access to innovative treatments. Unlike the traditional procurement methods that focus primarily on cost containment, VBP considers multiple factors, including the unique circumstances of each country, such as local disease burden, health priorities, infrastructure, supply chain, ability to pay for healthcare, and budget processes.

Economic Evaluation of Digital Health Technologies

Jul 2023

This webinar aims to provide insights into the economic evaluation of digital health technology, which presents unique challenges compared to pharmaceuticals, healthcare services, and medical devices. In this webinar, you will learn about the current role of health economics and outcomes research in assessing the value of digital health technologies, as well as the impact of digital health interventions in today’s healthcare systems.

Introduction to Open-Source Modeling: R We There Yet?

Apr 2023

In this forum, the OSM Special Interest Group has selected leaders in the field of health economics to describe their approach to OSMs. Mohsen Sadatsafavi will introduce the Peer Models Network and PRISM service as part of "Open-access modelling as a companion to open-source modelling” illustrated with an example implemented for Chronic Obstructive Pulmonary Disease (the Evaluation Platform in COPD (EPIC) model.)


Health Technology Assessment



Measuring Value in Oncology: Are We Keeping Pace with Science?

Mar 2024

This panel will discuss different perspectives on the utilization of these principles to advance value frameworks that help timely access to transformative treatments for people with cancer.

Application of Distributional Cost-Effectiveness Analysis to the US Setting

Sep 2023

This webinar will provide an educational opportunity for the ISPOR membership to learn about how distributional cost-effectiveness analysis (DCEA) can be applied in the US setting. This webinar will introduce the method, discuss the current state of foundational data in the US and highlight a recent case study to illustrate data sources that can be leveraged in more routine DCEA application.

Assessment of Digital Health Technologies in the Asia Pacific Region

Jun 2023

This webinar is based off discussions that were held at the 2023 ISPOR HTA Roundtable – Asia Pacific on 8 March 2023. The HTA Roundtable focused on how countries or jurisdictions in the Asia Pacific region are assessing digital health technologies. This webinar will provide perspectives from different stakeholders and jurisdictions on the status of digital health assessments in the region.

Challenges in Rare Disease Diagnostics: An Overview

Jun 2023

This webinar is aimed at all those who undertake research and development as well as value assessment of therapies and diagnostics in the rare disease space. It aims to expose the “diagnostic odyssey” and explain why a definitive diagnosis is not only important for patients but also for those assessing value. Objectives are to 1) explain what can be done to improve diagnosis in rare diseases and 2) why it matters in the context of value assessment.


Real-World Data & Information Systems


Revolutionizing Clinical Trials: Harnessing Real-World Evidence to Drive Diversity and Clinical Implementation

Apr 2024

In this session, we'll discuss leveraging RWE to enhance diversity within clinical trials and expedite the translation of research findings into real-world clinical practice. Our expert panel will illuminate how RWE can address existing disparities in clinical trial participation, amplify the voices of underrepresented communities, and ultimately lead to more effective and equitable healthcare interventions.

Tokenization in Clinical Trials: Benefits and End-to-End Enablement

Dec 2023

This webinar will provide a brief background on tokenization and its benefits. It will focus on end-to-end considerations for tokenizing data of clinical trial participants and designing fit for purpose studies based on linked real-world datasets.

The Use of Real-World Evidence in HTA in Central and Eastern Europe

Sep 2023

This webinar will cover the opportunities and challenges of collecting real-world data (RWD) and generating real-world evidence (RWE) for making better decisions in healthcare, specifically in Health Technology Assessment (HTA).

Assessing Causal Treatment Effect for Sequenced Oncology Regimens

Jul 2023

In oncology, sequential use of treatments with different mechanisms of action is common practice to overcome cross-resistance . Over the past decade, treatment sequencing with novel immunotherapy and targeted agents has contributed to substantial improvement in clinical outcomes in cancer patients. However, such clinical practice introduces methodology challenges for HTA.


Patient-Centered Research



Innovative Uses of Technology to Advance Health Preference Research

Sep 2023

Stated preference surveys often involve communicating large volumes of complex and/or unfamiliar medical information to provide context for respondents. This webinar examines innovative uses of technology to advance discrete choice experiment (DCE) research within health preference research. They will explore the different technologies that can be integrated into preference surveys illustrating how technology can better inform and potentially engage respondents.

FDA Patient-Focused Drug Development (PFDD) Guidance - Part 3

Jul 2023

With the public comment period open until July 2023, this webinar will also present ISPOR members with the opportunity to ask questions and provide comments that will help inform ISPOR’s response on the draft guidance 4 document.

Clinical Trial Innovation: How Healthcare Technology is Evolving

Jun 2023

Join us as we discuss how the healthcare landscape is changing in technology and clinical trial innovation, including diversity improvement, leveraging real-world evidence, comparative arms, and decentralized clinical trials.

FDA Patient-Focused Drug Development (PFDD) Guidance - Part 2

Mar 2023

In this webinar series, we will hear from patient representatives and FDA staff to learn what is covered in this guidance series and what these new guidances mean for patient-focused drug development and the HEOR community.

Medical Technologies



Digital Technologies for Health Systems: The African Experience

Dec 2023

This webinar focuses on important developments within the African continent. The main learning objectives are (1) to outline country experiences on rolling out digital health technologies, (2) discuss the role of big data analytics, and (3) describe the future prospects in the African context.

How to Drive Value in the Digital Transformation Era?

Sep 2023

The multi-stakeholder panel in this webinar will discuss how to strike the balance between openness and security in the process of health data collection for the successful value assessment regarding digital solutions.

Digital Endpoint Adoption: the How, What and Why

Feb 2023

Focusing on clinical neurosciences (CNS), and using first-hand experience from a Parkinson’s study, experts from Parexel discuss how to integrate eCOA science and sensor technology into clinical trials.

On the Validity of Statistical Analyses with Privacy-Preserving Synthetic Data

Sep 2022

This webinar presents a brief tutorial on synthetic data generation, an overview of its privacy preserving properties, and then review the results from studies evaluating the validity of analyses using synthetic data.

Methodical & Statistical Research



External Control Arms - Application, Key Methods, and Acceptability

Oct 2023

This webinar will address when and why external control arms (ECA) are used, the acceptable types of data and methods to build ECAs, and circumstances under which ECAs are accepted from regulatory and HTA bodies.

Applications of Large Language Models for RWD Analytics

Oct 2023

In this webinar, we will give an overview of LLMs and share practical advice and cutting-edge examples about how to use them to help carry out real-world evidence (RWE) studies. We will also show how integrating GPT into population health analytics enables complex real-world datasets to be explored using simple language queries to transform the way that decision makers use data to identify unmet health needs.

Harnessing Horses and Zebras in Predictive Analytics: Methodological Considerations for Extreme Population Sizes in Real-World Evidence Generation

Sep 2023

This webinar is aimed at those who perform or use the results of real-world evidence (RWE) studies. It aims to describe the use of predictive analytics and machine learning for causal inference in the context of the extremes for disease populations: rare diseases and common conditions such as obesity.

Assessing Causal Treatment Effect for Sequenced Oncology Regimens

Jul 2023

In oncology, sequential use of treatments with different mechanisms of action is common practice to overcome cross-resistance . Over the past decade, treatment sequencing with novel immunotherapy and targeted agents has contributed to substantial improvement in clinical outcomes in cancer patients. However, such clinical practice introduces methodology challenges for HTA.

Health Policy & Regulatory



The Global Socioeconomic Impact of Rare Diseases: A Call for Action

May 2024

The webinar will begin with a (5-minute) introduction of the participants of the study to the ISPOR Rare Disease (RD) SIG, followed by an overview of the study objectives, its methodology and findings (25-minute). This will be followed by a (30-minute) Q&A moderated discussion. The novel study explored the burden of different RDs across a range of countries, including low-and-middle-income countries (LMICs). The diseases and countries were chosen to allow for a diverse and relevant representation of RD burden globally, aiming to capture cross-disease and cross-country unmet needs, and consequent areas for policy intervention.

How Does Biosimilar Availability Create Value for the Patient? A Conversation About Avenues to Widen Access to Biologics

Oct 2023

The aim of this webinar is to discuss real-life examples on how biosimilar adoption has positively impacted care and patient access to biological therapies, focusing on testimonies from patient, policy, and healthcare professional representatives. Speakers are invited to converse on what the tangible benefits are that biosimilars have delivered for patients, and how biosimilar availability has supported access to care and the implementation of optimized disease management initiatives.

Health is Wealth

Jul 2023

This webinar will inaugurate the third edition of the series of webinars sponsored by FIFARMA on Value and Access to Innovation, and will be focused on exploring the relationship between health and the economy and how to ensure the long term healthcare system sustainability.

Challenges in Rare Disease Diagnostics: An Overview

Jun 2023

This webinar is aimed at all those who undertake research and development as well as value assessment of therapies and diagnostics in the rare disease space. It aims to expose the “diagnostic odyssey” and explain why a definitive diagnosis is not only important for patients but also for those assessing value. Objectives are to 1) explain what can be done to improve diagnosis in rare diseases and 2) why it matters in the context of value assessment.

Study Approaches


Revolutionizing Systematic Reviews: Harnessing the Power of AI

May 2024

This webinar will provide a comprehensive overview of the current landscape of AI adoption in systematic reviews and showcase several state-of-the-art platforms revolutionizing the systematic review process.

Communicating High Value in Scientific Publications

Sep 2023

This webinar will introduce several strategies for communicating the results of your study. These strategies can be used regardless of study methodology (eg, chart reviews, database analyses, economic models) and publication type (eg, abstract, poster, manuscript, report). As the field of HEOR continues to proliferate, the need for timely, clear, concise publications has never been greater.

Introduction to Open-Source Modeling: R We There Yet?

Apr 2023

In this forum, the OSM Special Interest Group has selected leaders in the field of health economics to describe their approach to OSMs. Mohsen Sadatsafavi will introduce the Peer Models Network and PRISM service as part of "Open-access modelling as a companion to open-source modelling” illustrated with an example implemented for Chronic Obstructive Pulmonary Disease (the Evaluation Platform in COPD (EPIC) model.)

Methods Maze: Pointers for Selecting Survival Extrapolation Models for Cancer Immunotherapy

Oct 2020

In this webinar, we will be discussing this issue in relation to cancer immunotherapy. An overview of the survival extrapolation methods which could be used for cancer immunotherapies will be presented along with an assessment of their strengths and limitations. Finally, the presenters will provide attendees with some pointers to help with the selection of appropriate survival extrapolation models for these agents.


Epidemiology & Public Health


Challenges in Rare Disease Diagnostics: An Overview

Jun 2023

This webinar is aimed at all those who undertake research and development as well as value assessment of therapies and diagnostics in the rare disease space. It aims to expose the “diagnostic odyssey” and explain why a definitive diagnosis is not only important for patients but also for those assessing value. Objectives are to 1) explain what can be done to improve diagnosis in rare diseases and 2) why it matters in the context of value assessment.

Health Equity in HEOR: Past, Present & Future Research Implications

Apr 2023

The webinar will provide an overview of past and current efforts in health equity, its role in health outcomes research, and its future implications in the field.

Availability and Access to Innovative Therapies in Latin America

Oct 2022

This webinar will focus on discussing how to ensure access for the right patient, to the right treatment, at the right time. We invited Max Newton, Engagement Manager at IQVIA as guest speaker. Max worked on the development of the FIFARMA "Patients Waiting to Access Innovative Therapies (WAIT) Indicator survey"; he also is leading a similar survey in Europe, the "EFPIA WAIT indicator".

Stakeholder Engagement in Value Assessment

Aug 2022

This is the Second webinar of the Value and Access to Innovation webseries sponsored by FIFARMA. The series are structured around FIFARMA's VAI working group workstreams: (1) Funding: what is the relation between health & the economy and how to ensure the long term healthcare system sustainability, (2) Value: what are the value frameworks used by decision makers in LatAm and what is the impact on patient access, (3) Adoption: how to ensure access for the right patient, to the right treatment, at the right time.


Specialized Treatment Areas


Looking Beyond Survival Data: Understanding the Value of Non-OS Endpoints in Oncology Reimbursement Decision-Making

Dec 2022

In this webinar, representatives from different stakeholder groups (patients, physicians, health economists and industry) will discuss the value of increasing the use of non-OS endpoints in reimbursement decision-making to their stakeholder groups. Using the example of multiple myeloma, the speakers will discuss how and when non-OS endpoints should be used, to support a future in which assessments of novel therapies are more fit-for-purpose.

Health Preference Research in the Context of Gene Therapy in Rare Diseases

Sep 2021

During this webinar, the speakers will present their respective studies on gene therapy in Duchenne muscular dystrophy, spinal muscular atrophy (SMA) and hemophilia. They will discuss the importance of the disease context, the qualitative research that influenced attribute selection, the selection of health preference method and design of the health preferences’ tasks, and how the study findings relate to the potential value of gene therapy.

Biosimilars: Market Access Challenges & Opportunities Worldwide

Feb 2021

This webinar will present an insightful exchange on best practices, challenges and opportunities for market access of biosimilars in different regions worldwide.

Biosimilars: Unleashing The Potential For Improved Patient Access And Cost Savings In The United States

Oct 2020

The webinar will present an overview of societal benefits of biosimilars, how these are measured, how the United States (US) and select markets are tracking in attaining these benefits, and potential solutions for advancing the evidence of potential benefits into action.


Specific Diseases & Conditions


Looking Beyond Survival Data: Understanding the Value of Non-OS Endpoints in Oncology Reimbursement Decision-Making

Dec 2022

In this webinar, representatives from different stakeholder groups (patients, physicians, health economists and industry) will discuss the value of increasing the use of non-OS endpoints in reimbursement decision-making to their stakeholder groups. Using the example of multiple myeloma, the speakers will discuss how and when non-OS endpoints should be used, to support a future in which assessments of novel therapies are more fit-for-purpose.

Implications of Matched Adjusted Indirect Treatment Comparisons in Rare Disease

Jun 2021

A one-hour educational webinar on the implications of matched adjusted indirect treatment comparisons in rare disease, using SMA as an example. Webinar will provide both statistical and clinical perspective.

Challenges in Assessing the Clinical and Economic Value of Future Treatments for Alzheimer’s Disease

Feb 2021

This educational webinar will describe factors that affect the assessment of the clinical and economic value of medical innovations, highlight specific issues with relevance to the societal value of treatments for AD, and place these issues in the context of future health technology assessments for AD treatments.

Long Term Value Demonstration in Alzheimer’s Disease: Evidence Needs

Dec 2020

This educational webinar explores some of the key issues relating to long-term evidence needs within the context of HTA in AD and considers what can be done in the short, medium, and long term to address evidence needs.

Need More Information or Have Questions?

Contact us for more information on ISPOR education and training.

Contact Us

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×